The Vistin Pharma group was established in June 2015, when Vistin Pharma AS acquired the B2B business (metformin and opioid APIs) and tablet production assets of Weifa AS. With more than 75 years of pharmaceutical industry experience, the Group has built significant capacity and expertise as an API and Solid Dosage Form provider to producers all over the world, and Vistin Pharma‘s APIs are marketed in more than 100 countries.
On 2nd October 2017 Vistin Pharma sold its opioids and tablet CMO business to TPI Enterprises. After the demerger, Vistin Pharma has become a pure play global metformin supplier. The production of metformin was introduced in 1969 (formerly as Weifa), and has since then been developed to include the supply of metformin HCl (hydrochloride) and metformin DC (direct compressible). These products make up Vistin Pharma’s metformin offering. The company built and opened a new a state-of-the-art metformin manufacturing plant in 2002 and has grown to become one of the leading global suppliers of metformin. The products are sold to recognized international pharmaceutical companies across the world. In April 2020 the company announced its decision to invest in doubling the manufacturing capacity at its plant in Fikkjebakke, Norway with a goal to further strengthen its position as a leading global player in the ever growing metformin market.